Introduction Chronic myelogenous leukemia (CML) in pediatric and adolescent populations is relatively rare. The present study provides an integrated approach to evaluate the impact of molecular and cytogenetic response on long-term outcomes in these populations by incorporating demographic factors and hematological parameters, and to explore their clinical relevance in resource-limited settings. Material and methods A retrospective analysis was conducted on patients 10 years had five-year survival rates of 100% and 88%, respectively. Conclusion The achievement of molecular and cytogenetic responses has a significant impact on long-term outcomes in pediatric and adolescent patients diagnosed with CML, highlighting their role as crucial predictors in clinical practice. Patients who achieved both MMR and CCyR demonstrated 100% five-year overall survival (OS), while those with EMR showed a 97.4% five-year survival. These findings support the utility of early response monitoring to inform prognosis and guide therapy, particularly in low- and middle-income countries (LMICs). However, treatment abandonment and poor compliance remain major obstacles in LMICs. Further research with multicentric prospective trials in LMICs is essential.
Dave et al. (Mon,) studied this question.